Filing Details

Accession Number:
0001847903-24-000169
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-15 16:30:47
Reporting Period:
2024-11-13
Accepted Time:
2024-11-15 16:30:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1847903 Centessa Pharmaceuticals Plc CNTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1861926 Saurabh Saha C/O Centessa Pharmaceuticals Plc
3Rd Fl., 1 Ashley Rd, Altrincham
Cheshire X0 WA14 2DT
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2024-11-13 32,023 $5.84 662,684 No 4 M Direct
Ordinary Shares Disposition 2024-11-13 32,023 $18.28 630,661 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Option (right to buy) Disposition 2024-11-13 32,023 $0.00 32,023 $5.84
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,962,462 2031-02-19 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 38,000 Indirect By trust
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.23 to $18.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.
  5. 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.